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S U M M A R Y
Objectives: Helicobacter pylori is a bacterium that infects over 50% of the human population worldwide.
An increasing number of studies have demonstrated that H. pylori may cause liver diseases, and the
underlying relationship between H. pylori infection and chronic hepatitis B has attracted much attention.
This study aimed to examine the association between H. pylori infection and the progression of chronic
hepatitis B in the Chinese population.
Methods: A search was performed of the PubMed/MEDLINE, Web of Science, and Cochrane Central
Register of Controlled Trials (CENTRAL) databases, as well as the Chinese databases, China National
Knowledge Infrastructure and Wanfang Data, for studies published between January 1, 1994 and
November 1, 2015.
Results: In total, 2977 patients were included in the chronic hepatitis B group, while 1668 participants
were included in the healthy control group. The prevalence of H. pylori among patients with chronic
hepatitis B was signiﬁcantly higher than that among those without chronic hepatitis B. The pooled odds
ratio was 3.17. In the subgroup analysis, the odds ratio was 4.28 for hepatitis B virus (HBV)-related
cirrhosis and 6.02 for hepatocellular carcinoma.
Conclusion: These results indicate a strong relationship between H. pylori and chronic hepatitis B,
particularly during HBV progression.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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More than 350 million individuals worldwide are infected with
the hepatitis B virus (HBV), and HBV infection remains a huge
global health problem.1 HBV infection is also highly prevalent in
China,2 with more than 120 million HBV carriers.3 HBV infection is
the main cause of liver disease, with 25–30% of infected individuals* Corresponding authors. Tel./Fax: +0731-84327392.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ultimately developing hepatic cirrhosis, end-stage liver disease, or
hepatocellular carcinoma (HCC), and even dying.4,5 Moreover, the
estimated incidence rate of HCC in China is 27.29/105 world
standard population.6 However, the factors that affect the
development of cirrhosis and/or HCC in HBV carriers are poorly
understood.7
Helicobacter pylori infects over 50% of the human population and
usually colonizes the gastric mucosa.8 In 1994, the World Health
Organization recognized H. pylori as a group 1 carcinogen contrib-
uting to gastric cancer.9 More than 600 million Chinese people are
positive for H. pylori infection.10 Populations of low socioeconomic
status are especially at risk of H. pylori infection.11H. pylori infection
is associated with chronic gastritis, peptic ulcer disease, and MALT
lymphoma, in addition to gastric adenocarcinoma.12 Researchersociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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diseases, such as hematological diseases, cardiovascular diseases,
and especially liver diseases.13,14
In the late 1990s, Fan et al. and Ponzetto et al. demonstrated
that the rate of H. pylori infection in patients with chronic hepatitis
B (CHB) was much higher than that in healthy individuals.15,16 In
2001, de Magalha˜es Queiroz and Santos reported the presence of
H. pylori in the livers of patients with Wilson’s disease.17 Recently,
a growing number of studies have been conducted to determine
the relationship between H. pylori infection and both HBV-related
cirrhosis and HBV-related HCC in the Chinese population.18,19
However, the association between H. pylori infection and the
progression of HBV-related liver diseases remains unclear. The aim
of this study was to explore the relationship between H. pylori
infection and the progression of CHB by performing a systematic
review.
2. Materials and methods
2.1. Search strategy
The following databases were used in this study: PubMed/
MEDLINE, Web of Science, and the Cochrane Central Register of
Controlled Trials (CENTRAL), as well as two Chinese databases,
China National Knowledge Infrastructure (CNKI) and Wanfang
Data. The keywords or subject headings used were ‘‘hepatitis B’’
and ‘‘H. pylori, Helicobacter pylori, or Helicobacter species’’, from the
earliest date available to November 1, 2015. The bibliographies of
selected original studies, reviews, and relevant advance abstracts
were screened.
2.2. Study selection
For each eligible study, the title and/or abstract was screened
independently by two reviewers against speciﬁc criteria: (1) an
original cross-sectional or case–control study, or a randomized
controlled trial (RCT), comparing H. pylori-related morbidity
between patients with CHB and healthy controls; (2) study
reporting the absolute numbers of cases and controls as well as
the positive rate of H. pylori infection; (3) study groups
conﬁrmed to be HBV-positive and control groups HBV-negative,
with H. pylori being detected using serological tests. All studies
had to have been performed in China. Finally, studies were
excluded if they included patients with other viral hepatitis
etiologies (e.g., hepatitis A, C, or E virus) or other types of
hepatitis, such as autoimmune liver disease and non-alcoholic
fatty liver disease.
2.3. Data extraction and quality assessment
The following data were collected from each original study: ﬁrst
author, year of publication, numbers included in the two groups
(CHB and control), incidence of H. pylori infection in the two
groups, and the numbers of patients with CHB who had no
cirrhosis, cirrhosis present, and HCC. Discrepancies were resolved
by consensus between the two reviewers. Finally, 15 case–control
studies were included. The Newcastle–Ottawa Scale was used to
assess the methodological quality of the studies.20
2.4. Statistical analysis
The meta-analysis was performed using Stata 12.0 (StataCorp,
College Station, TX, USA). Risk ratios (RRs) were used to assess the
risk estimate for RCTs. Odds ratios (ORs), which were considered
approximate RRs in this meta-analysis, were used for case–control
studies. The heterogeneity of the studies was evaluated using theChi-square test and I2 statistic. The ﬁxed-effects model was used if
the heterogeneity was insigniﬁcant (Chi-square test p  0.10 and I2
 50%), while the random-effects model was preferred if
signiﬁcant heterogeneity was found (Chi-square test p < 0.10 or
I2 > 50%). Egger’s regression test and the trim and ﬁll method were
used to analyze publication bias.
3. Results
A total of 15 case–control studies were included from
333 studies identiﬁed in the online search. The process of selection
and analysis is shown in the ﬂow diagram in Figure 1. A description
of the included studies is given in Table 1.15,21–34
3.1. H. pylori-positive rate in the HBV and control groups
In the meta-analysis (Figure 2), the heterogeneity of all
15 studies was found to be signiﬁcant (I2 = 77.9%). Using a
random-effects model, the pooled OR was 3.17 (95% conﬁdence
interval (CI) 2.38–4.22; p < 0.01), indicating that the H. pylori-
positive rate in patients with CHB is approximately 3.17 times that
in the healthy population.
3.2. Subgroup meta-analysis according to HBV stage
In order to attenuate the inﬂuence of HBV disease stage on the
results of the meta-analysis, the extracted data of the included
studies were classiﬁed into non-cirrhosis, cirrhosis, and HCC
groups, and these groups were compared with the control group.
Forest plots of the meta-analysis are shown in Figure 3. For patients
with CHB only, the H. pylori-positive rate in patients without
cirrhosis or HCC was 2.44-fold higher than that in healthy controls
(pooled OR 2.44, 95% CI 1.85–3.24; p < 0.01). With HBV progres-
sion, patients with cirrhosis and HCC might have a higher risk of
acquiring an H. pylori infection. The H. pylori-positive rate in
patients with CHB and cirrhosis was 4.28-fold higher (pooled OR
4.28, 95% CI 2.99–6.13; p < 0.01) than that in the healthy
population, while it was 6.02-fold higher (pooled OR 6.02, 95%
CI 4.33–8.37; p = 0.821) in patients with HBV-related HCC. Because
the heterogeneities were both signiﬁcant (I2 > 50%) in Figure 3A
and 3B, a random-effects model was used for the calculations,
while a ﬁxed-effects model was used for the data in Figure 3C.
3.3. Evaluation of sensitivity analysis
In order to determine the inﬂuence of each individual study on
the pooled OR, a sensitivity analysis was performed by the
omission of individual studies. Pooled OR values were not
signiﬁcantly affected by any individual study (Figure 4).
3.4. Evaluation of publication bias
Egger’s regression test was used to assess publication bias in the
15 studies included in the meta-analysis (Figure 5A). The graph
appeared asymmetric, which indicates that a risk of publication
bias may exist. The trim and ﬁll method was used to determine
whether the results were reliable. Before and after trimming and
ﬁlling, the 95% CI of the result was 1.153 (0.868–1.438) and 1.122
(0.836–1.409), respectively, using a random-effects model. As
shown in Figure 5B, this means that the results of the study are
stable and reliable.
4. Discussion
Both H. pylori and HBV infection are prevalent in China, and
many researchers have found a relationship between H. pylori and
Figure 1. Flow diagram of the study selection and analysis process (HBV, hepatitis B virus; HCC, hepatocellular carcinoma).
J. Wang et al. / International Journal of Infectious Diseases 50 (2016) 30–3732HBV-related liver disease. H. pylori may be a putative risk factor in
the development of HBV. A meta-analysis was conducted to
explore H. pylori infection and the progression of CHB.
This study showed that the H. pylori-positive rate of patients
with CHB was higher than that in the healthy population. HuangTable 1
Characteristics of the studies included
Study Number of starsa Number of H. pylori-p
subjects in the two gr
Control 
Fan XG, 199815 7 44/104 
Wu MS, 200021 6 1/30 
Hu XH, 200322 7 17/30 
Xuan SH, 200523 7 13/35 
Yang ZA, 200624 6 4/50 
Zhang YG, 200825 8 190/328 
Ji SW, 200826 8 186/429 
Gao CE, 200927 8 121/300 
Li BS, 201128 7 90/208 
Fan RQ, 201229 8 26/76 
Ge WM, 201330 7 66/147 
Wang GS, 201331 8 24/60 
Xi JD, 201532 7 18/70 
Yu K, 201533 8 10/43 
Gao HQ, 201534 8 46/120 
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; NR, not reported.
a Newcastle–Ottawa scale.et al. demonstrated that oral inoculation with H. pylori leads to
hepatitis of varying severity in mice. They also found that speciﬁc
H. pylori genes could be detected in murine liver samples.35 Huang
et al. concluded that H. pylori reach the liver via the blood stream or
the biliary system and then become an independent etiologicalositive
oups, n/N
Number of H. pylori-positive HBV subjects by stage of
HBV progression, n/N
HBV Non-cirrhosis Cirrhosis HCC
55/96 NR NR NR
47/108 32/76 15/32 NR
50/80 NR 50/80 NR
30/45 NR NR NR
79/128 NR NR NR
228/376 150/167 51/73 27/36
321/502 228/383 64/83 29/36
189/296 140/228 49/68 22/27
157/246 NR NR NR
107/167 51/71 35/68 21/28
113/215 71/154 42/61 NR
200/273 52/83 97/126 51/64
180/246 44/72 85/105 51/69
149/201 35/56 70/86 44/59
84/120 24/38 46/64 14/18
Figure 2. Forest plot of the meta-analysis for the Helicobacter pylori-positive rate between the HBV group and the control group.
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reported that H. pylori exert cytopathic effects on hepatocytes in
vitro.36,37 The present study results are consistent with these
ﬁndings.
Heterogeneity was signiﬁcant in the studies above. Although a
sensitivity analysis was performed, no single article that could
inﬂuence the result by itself was found. Consequently, the random-
effects model was used. The source of the heterogeneity could be
the difference in constituent ratios of CHB disease progression
between the studies. To address this, a subgroup analysis of
patients at different disease stages was performed. Differences in
viral load of patients with CHB could also have contributed to the
heterogeneity. Xi et al. reported that the rate of H. pylori infection
in patients with HBV-DNA >103 copies/ml was higher than that in
patients with HBV-DNA <103 copies/ml.32 In contrast, Wang et al.
and Ji et al. showed that there was no signiﬁcant difference in the
prevalence rate of H. pylori in CHB patients with different levels of
HBV-DNA.26,31
Genotype B and C are the major HBV genotypes in China.
Genotype B is predominant in northern China, while genotype C is
more common in southern China.38 HBV genotypes contribute to
the response to antiviral therapy and the risk of HCC, and the HBV
genotype might be a risk factor for HCC recurrence.39 Unfortu-
nately, since none of the studies included here mentioned the
genotypes, it was not possible to further analyze the inﬂuence of
HBV genotype on H. pylori prevalence in patients with CHB.
All of the studies included reported a higher prevalence of
H. pylori infection in patients with cirrhosis. However, Hu and
Deng22 and Xi32 reported that the prevalence of H. pylori infectionis signiﬁcantly higher in patients with more severe cirrhosis as
assessed by Child–Pugh class, while Wang et al.31 reported no
signiﬁcant difference. Thus, the difference in Child–Pugh class in
each study may account for the heterogeneity in the group with
HBV-related cirrhosis.
This study also suggested that H. pylori incidence correlates
positively with HBV-related HCC. Huang et al. detected H. pylori
in HBV-related primary HCC using morphological and immuno-
histochemical methods.40 They inferred that H. pylori could be a
risk factor for HCC progression. Abu Al-Soud et al. reported that
the presence in liver specimens of Helicobacter DNA (H. pylori
was the most prevalent species), but not that of other common
gut bacteria, was associated with human hepatic carcinogene-
sis.19 These ﬁndings are consistent with the present study
results.
This study has some limitations. First, the results showed
moderate publication bias using Egger’s test. However, when fewer
than 20 trials are included, the sensitivity of Egger’s test for meta-
analyses is usually low.41 Consequently, the trim and ﬁll method
showed the results to be stable and reliable. Additionally, the
results of the meta-analysis may have been affected by the
limitations of the publications included. Although great care was
taken to identify all related studies, some may have been
overlooked. In addition, some studies might not have been
published because of negative results, which would lead to an
unavoidable publication bias. Moreover, all articles that were
included were published in English or Chinese and originated in
China. Thus, the results may not be representative of other non-
Chinese populations. This study was further limited by the
Figure 3. Forest plots of the meta-analysis according to the HBV progression stage: (A) Helicobacter pylori positivity rate between the non-cirrhosis group and the control
group; (B) Helicobacter pylori positivity rate between the cirrhosis group and the control group; (C) Helicobacter pylori positivity rate between the HBV-related hepatocellular
carcinoma group and the control group.
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Figure 3 (Continued ).
J. Wang et al. / International Journal of Infectious Diseases 50 (2016) 30–37 35inclusion of only case–control studies. The quality of such studies
is lower than that of RCTs.
In summary, the results of this study revealed that H. pylori
infection is positively associated with CHB and particularly with
HBV-related cirrhosis and HBV-related HCC. Therefore, it is vital toFigure 4. Sensitivity analysisscreen patients with CHB for H. pylori infection. Moreover, these
results highlight the urgent need for H. pylori eradication.
Unfortunately, due to the limited number of studies included,
additional RCTs should be conducted to further support the
ﬁndings of this study. of the studies included.
Figure 5. A Egger’s funnel plot—the Egger’s funnel plot showed the existence of a small publication bias. (B) Trim and ﬁll method—just ﬁlling one study corrected the
publication bias, indicating the results to be reliable.
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